Table 1.
Characteristics of patients
| Patient | Sex | Age, y | Treatment | WBC count, × 109/L | Rai stage | CD38 | Interphase cytogenetics* |
|---|---|---|---|---|---|---|---|
| 1 | M | 55 | None | 20 | 1 | – | NA |
| 2 | M | 85 | Chlorambucil† | 68 | 3/4 | NA | NA |
| 3 | M | 47 | Multiple | 40 | 1 | – | Normal |
| 4‡ | NA | NA | NA | NA | NA | NA | NA |
| 5 | F | 70 | None | 60 | 0 | NA | NA |
| 6 | M | 47 | None | 30 | 1 | – | NA |
| 7 | F | 54 | Chlorambucil§ | 16 | 0 | + | +12 13q |
| 8 | M | 57 | None | 200 | 1 | NA | 13q |
| 9 | M | 50 | None | 37 | 1 | NA | NA |
| 10 | M | 75 | Multiple∥ | 100 | 3/4 | – | 13q |
| 11 | M | 61 | None | 69 | 1 | + | 13q 11q |
| 12 | F | 79 | Multiple¶ | 34 | 1 | NA | NA |
| 13 | F | 69 | None | 107 | 1 | + | Normal |
| 14 | M | 52 | Fludarabine# | 200 | 2 | + | Normal |
| 15 | F | 52 | None | 42 | 1 | NA | NA |
| 16 | F | 57 | None | 300 | 1 | + | +12 t(1;6) |
| 17 | M | 75 | Multiple** | 21 | 2 | + | 13q |
| 18 | F | 57 | None | 219 | 1 | – | 13q 6q |
| 19 | F | 56 | None | 72 | 1 | + | +12 |
WBC indicates white blood cell; NA, information not available.
*
The only patients from which variable heavy chain (VH) gene mutational status was available were patients 8 and 10, both having VH unmutated
†
Rituximab, cyclophosphamide, vincristine, and prednisone (2000)
‡
Patient 4 entered the study in condition of anonymity
§
Treatment received in 2003 and 2004
∥
Fludarabine/mitoxantrone (1999); cyclophosphamide, vincristine, and prednisone/rituximab (2003); alemtuzumab (2003)
¶
Chlorambucil (1992–2000); rituximab, cyclophosphamide, vincristine, and prednisone (2002)
#
Treatment received in 2001
**
Pentostatin/cyclophosphamide/rituximab (2003 and 2004)